Benchmark King Pharmaceuticals' Performance against Key Rivals.LYON, France -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. King Pharmaceuticals King Pharmaceuticals (NYSE: KG), the world's 39th largest pharmaceutical company, is based in Bristol, Tennessee.[1][2] King produces a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a : PharmaVitae Profile To order that report: www.reportlinker.com/p064473/King-Pharmaceuticals- PharmaVitae-Profile.html (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the browser's address field. Remove the extra space if one exists.) For more information, contact Nicolas by email nbo@reportlinker.com , or by phone +33 4 37 65 17 03. This analysis examines the historical and forecast performance for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually con·tin·u·al adj. 1. Recurring regularly or frequently: the continual need to pay the mortgage. 2. updated quantitative and qualitative information. Scope Benchmark King Pharmaceuticals' performance against key rivals in the ethical pharmaceutical sectorSee how King's future depends on the success of its launch portfolio following the patent expiry of several of the company's key products CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 3 Therapeutic strategy 5 Launch and expiry outlook 7 Externalization The ability to easily connect to and transfer information between business partners. Increasingly, information systems are designed to make their data available to outside partners and customers. This type of collaboration is expected to be a vital part of IT in the 21st century. See EDI. , geographic and molecule type strategies 10 Externalization strategy 11 Geographic strategy 12 Molecule type strategy 12 SWOT analysis SWOT Analysis A tool that identifies the strengths, weaknesses, opportunities and threats of an organization. 13 Strengths 13 Weaknesses 14 Opportunities 14 Threats 15 CHAPTER 2 CORPORATE HISTORY 20 Key findings 20 Background 21 Key corporate developments 21 M&A history 22 Medco Research and Jones Pharma mergers 22 Acquisition of Meridian Meridian (mərĭd`ēən), city (1990 pop. 41,036), seat of Lauderdale co., E Miss., near the Ala. line; settled 1831, inc. 1860. Medical Technologies and Elan's primary care business 22 Mylan Laboratories terminates acquisition agreement 22 Current corporate structure 23 Pharmaceuticals 23 Meridian Medical Technology 23 Current management team 24 CHAPTER 3 HISTORICAL PERFORMANCE 25 Key findings 25 Introduction 26 Revenue and growth rate analysis, 2001-06 26 Revenue and growth rate vs. peer set 27 Product analysis, 2001-06 29 Growth drivers 29 Skelaxin 29 Altace Altace® Ramipil Vascular disease An ACE inhibitor antihypertensive Adverse effects Headache, fatigue, dizziness, dry cough, angioedema Contraindications Hx of angioedema. See ACE inhibitor. 30 Thrombin-JMI 30 Sonata sonata (sənä`tə), in music, type of instrumental composition that arose in Italy in the 17th cent. At first the term merely distinguished an instrumental piece from a piece with voice, which was called a cantata. 30 Growth resistors 31 Rest of portfolio 31 Operating revenue operating revenue Revenue from any regular source. Revenue from sales is adjusted for discounts and returns when calculating operating revenue. Compare other revenue. and cost analysis, 2001-06 32 Operating revenue/cost analysis 34 CHAPTER 4 FORECAST PERFORMANCE 36 Key findings 36 Introduction 37 Revenue and growth rate, 2006-12 37 Product analysis, 2006-12 39 Growth drivers 44 Altace HCTZ HCTZ abbr. hydrochlorothiazide 44 Remoxy 44 Avinza 44 Growth resistors 45 Altace 45 Skelaxin 45 Thrombin-JMI 45 Sonata 45 Therapy area analysis, 2006-12 47 Therapy area growth drivers 49 Central nervous system 49 Therapy area growth resistors 50 Cardiovascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels. car·di·o·vas·cu·lar adj. Abbr. & hematology hematology Branch of medicine concerned with the nature, function, and diseases of the blood. It covers the cellular and serum composition of blood, the coagulation process, blood-cell formation, hemoglobin synthesis, and disorders of all these. 50 Therapy area focus 50 Launches and expiries analysis, 2006-12 53 Launch portfolio 53 Avinza (morphine sulfate morphine sulfate, n brand names: Duramorph PF, MS Contin, Roxanol; drug class: narcotic analgesic (Controlled Substance Schedule II); action: ) 54 Altace HCTZ (ramipril ramipril /ra·mi·pril/ (rah-mi´pril) an angiotensin-converting enzyme inhibitor used in treatment of hypertension and congestive heart failure and the prevention of a major cardiovascular event in high-risk patients. + hydrochlorothiazide hydrochlorothiazide /hy·dro·chlo·ro·thi·a·zide/ (-klor?o-thi´ah-zid) a thiazide diuretic, used for treatment of hypertension and edema. hy·dro·chlo·ro·thi·a·zide n. Abbr. ) 54 Remoxy (oxycodone oxycodone /oxy·co·done/ (-ko´don) an opioid analgesic derived from morphine; used in the form of the hydrochloride and terephthalate salts. ox·y·co·done n. ) 55 Core portfolio 56 Expiry portfolio 58 Thrombin-JMI 58 Altace 58 Skelaxin 59 Sonata 59 Launch/core/expiry configuration 60 Externalization analysis, 2006-12 63 Geographic analysis, 2006-12 68 Molecule type analysis, 2006-12 72 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 77 Key findings 77 Overview 78 Central nervous system 79 Avinza 79 Overview 79 Sales forecast 80 Newsflow 80 Current market assessment 81 Future market assessment 81 Remoxy 83 Overview 83 Sales forecast 84 Newsflow 84 Future market assessment 85 Competitive landscape 86 Opioid analgesics Analgesics, Opioid Definition Opioid analgesics, also known as narcotic analgesics, are pain relievers that act on the central nervous system. Like all narcotics, they may become habit-forming if used over long periods. market dominated by key brands and generic competitors 86 The opioid opioid /opi·oid/ (o´pe-oid) 1. any synthetic narcotic that has opiate-like activities but is not derived from opium. 2. any of a group of naturally occurring peptides, e.g. class: potential for abuse 86 Skelaxin 87 Overview 87 Sales forecast 88 Newsflow 88 Current market assessment 89 Future market assessment 89 Cardiovascular & hematology 90 Altace 90 Overview 90 Sales forecast 91 Newsflow 91 Altace HCTZ 94 Overview 94 Sales forecast 95 Newsflow 95 R&D pipeline 97 CHAPTER 6 APPENDIX 98 IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. vs. company-reported data reconciliation 98 References 100 Abbreviations 101 List of Tables Table 1: King's Corporate Executive Committee 24 Table 2: Peer set overview 27 Table 3: Operating revenue/cost analysis ($m), 2001-06 32 Table 4: Operating cost ratio analysis (% of total revenues), 2001-06 34 Table 5: Product portfolio overview, sales ($m), 2006-12 39 Table 6: Therapy area overview, sales ($m), 2006-12 47 Table 7: Launch portfolio overview, sales ($m), 2006-12 53 Table 8: Core portfolio overview, sales ($m), 2006-12 56 Table 9: Expiry portfolio overview, sales ($m), 2006-12 58 Table 10: Externally developed portfolio ($m), 2006-12 63 Table 11: Molecule type overview, sales ($m), 2006-12 72 Table 12: Key products overview 78 Table 13: Avinza: overview 79 Table 14: Avinza: sales forecast ($m), 2006-12 80 Table 15: Avinza: newsflow 80 Table 16: Remoxy: overview 83 Table 17: Remoxy: sales forecast ($m), 2006-12 84 Table 18: Remoxy: newsflow 84 Table 19: Skelaxin: overview 87 Table 20: Skelaxin: sales forecast ($m), 2006-12 88 Table 21: Skelaxin: newsflow 88 Table 22: Altace: overview 90 Table 23: Altace: sales forecast ($m), 2006-12 91 Table 24: Altace: newsflow 91 Table 25: Altace HCTZ: overview 94 Table 26: Altace HCTZ: sales forecast ($m), 2006-12 95 Table 27: Altace HCTZ: newsflow 95 Table 28: King Pharmaceuticals pipeline (Phase I-registration) 97 List of Figures Figure 1: Historical and forecast ethical sales performance (% CAGR CAGR See: Compound Annual Growth Rate ), King Pharmaceuticals and Mid Pharma peer set 3 Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006 5 Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), King Pharmaceuticals 7 Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 8 Figure 5: Key strategic products, sales ($m), 2006-12 9 Figure 6: Molecule type, externalization and geographic market dependency dependency In international relations, a weak state dominated by or under the jurisdiction of a more powerful state but not formally annexed by it. Examples include American Samoa (U.S.) and Greenland (Denmark). (%) vs. peer set, 2006 10 Figure 7: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 11 Figure 8: SWOT analysis of King Pharmaceuticals 13 Figure 9: Current corporate structure 23 Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06 26 Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06 28 Figure 12: Growth drivers/resistor products of historical revenue performance ($m), 2001-06 29 Figure 13: Operating revenue/cost analysis ($m), 2001-06 33 Figure 14: Operating cost ratio analysis (% of total revenues), 2001-06 35 Figure 15: Ethical revenue ($m) and growth rate (%), 2006-12 38 Figure 16: Top five products by sales ($m), 2006 40 Figure 17: Top five products by sales ($m), 2012 41 Figure 18: Growth drivers and resistors by product, 2006-12 43 Figure 19: Key strategic products, sales ($m), 2006-12 46 Figure 20: Ethical sales by therapy area ($m), 2006-12 48 Figure 21: Growth drivers and resistors by therapy area ($m), 2006-12 49 Figure 22: Ethical sales by therapy area (%), 2006-12 50 Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2006 51 Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2012 52 Figure 25: Launch schedule, sales ($m), 2006-12 55 Figure 26: Core products sales growth ($m), 2006-12 57 Figure 27: Expiry schedule, sales ($m), 2006-12 59 Figure 28: Launch, core and expiry, sales ($m), 2006-12 60 Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), King Pharmaceuticals 61 Figure 30: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 62 Figure 31: Externalization dependency, sales ($m), 2006-12 64 Figure 32: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12 65 Figure 33: Externalization dependency vs. peer set, % total sales, 2006 66 Figure 34: Externalization dependency vs. peer set, % total sales, 2012 67 Figure 35: Geographical sales breakdown ($m), 2006-12 68 Figure 36: Growth drivers and resistors by geography, sales ($m) 2006-12 69 Figure 37: US dependency vs. peer set, % total sales, 2006 70 Figure 38: US dependency vs. peer set, % total sales, 2012 71 Figure 39: Molecule type sales breakdown ($m), 2006-12 73 Figure 40: Growth drivers/ resistors by molecule type, sales ($m), 2006-12 74 Figure 41: Biologics dependency vs. peer set, % total sales, 2006 75 Figure 42: Biologics dependency vs. peer set, % total sales, 2012 76 Figure 43: IMS vs. company-reported ethical sales discrepancy DISCREPANCY. A difference between one thing and another, between one writing and another; a variance. (q.v.) 2. Discrepancies are material and immaterial. ($m), 2006 99 Figure 44: IMS vs. company-reported ethical sales forecast growth rates Growth Rates The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures. Notes: Remember, historically high growth rates don't always mean a high rate of growth looking into the future. (%), 2006-12 100 More market research reports? Go to http://www.reportlinker.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion